Skip to main content
OpenTrials

Clinical trial condition

Neoplastic Syndromes, Hereditary

Explore clinical trials studying Neoplastic Syndromes, Hereditary. Study availability and eligibility vary by location and protocol.

869 public trials 154 recruiting studies
Refine in advanced search Browse all conditions

Neoplastic Syndromes, Hereditary trial results

Active, Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620

Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, +99 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 172 locations
View Trial Details
Active, Not Recruiting

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

NCT02867592

Conditions
Adenocarcinoma, Adrenal Cortex Diseases, Adrenal Cortex Neoplasms, +92 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Kaiser Permanente-Anaheim Anaheim, California, United States
View all 142 locations
View Trial Details
Active, Not Recruiting

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

NCT02359565

Conditions
Brain Diseases, Brain Neoplasms, Brain Stem Neoplasms, +46 more
Locations
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States
  • Children's Hospital Colorado Aurora, Colorado, United States
  • Children's National Medical Center Washington D.C., District of Columbia, United States
View Trial Details
Active, Not Recruiting

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

NCT03190915

Conditions
Bone Marrow Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, +22 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Kaiser Permanente Downey Medical Center Downey, California, United States
View all 57 locations
View Trial Details
Active, Not Recruiting

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

NCT02760849

Conditions
Adnexal Diseases, Breast Diseases, Breast Neoplasms, +33 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mayo Clinic Rochester, Minnesota, United States
  • Siteman Cancer Center at Washington University St Louis, Missouri, United States
View Trial Details
Active, Not Recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04284774

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Endocrine Gland Neoplasms, Endocrine System Diseases, +102 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 172 locations
View Trial Details
Active, Not Recruiting

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

NCT03962543

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +18 more
Locations
  • University of Alabama at Birmingham/Children's of Alabama Birmingham, Alabama, United States
  • Mayo Clinic Arizona Phoenix, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Children's Hospital Los Angeles Los Angeles, California, United States
View all 43 locations
View Trial Details
Active, Not Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

NCT03213652

Conditions
Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +82 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 126 locations
View Trial Details

Related conditions